iBrands Corporation Provides Update to Shareholders
iBrands Corporation (OTC PINK: IBRC) announces significant updates for shareholders. The Company plans to initiate an audit to become a fully reporting SEC entity. A Master Sales Agreement has been established with Therapeutic Solutions Inc. to distribute a nutraceutical line, which includes products like QuadraMune. The clinical trial of QuadraMune, aimed at preventing COVID-19, is registered on ClinicalTrials.gov. The Company is also seeking additional distribution partners and aims to increase online sales through SEO strategies.
- Initiation of an audit to become a fully reporting SEC entity.
- Master Sales Agreement with Therapeutic Solutions Inc. for nutraceutical product distribution.
- Positive clinical trial results for QuadraMune, indicating enhanced immune activity.
- None.
LAS VEGAS, March 30, 2021 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC PINK: IBRC) ("the Company"), a diversified holding and branding company, announces a update to shareholders and interested parties.
Dear Shareholders,
Please see below updates:
OTC Markets Current Information
The Company intends to have an audit conducted on the business and become an SEC fully reporting company.
Therapeutic Solutions Inc. Master Sales Agreement
The company entered into a Master Sales Agreement with Therapeutic Solutions Inc. (“TSOI”) to distribute the nutraceutical line of products developed by TSOI for sales through its iBrands Farms subsidiary.
Products to be included in the Master Sales Agreement currently consist of NanoStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, ProJuvenol, and Immune Booster Quadramune.
A clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is now on the Federal Clinical Trial registry: https://www.clinicaltrials.gov/ct2/show/NCT04421391.
Other exciting developments from this license include the public information release from TSOI includes “QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer New Patent Filing Suggests Novel Mechanism of Immune Boosting Nutraceutical Can Augment Efficacy of Cancer Immunotherapy.” and, “Positive QuadraMune™ Clinical Trial Data,” which suggests data from its clinical trial demonstrating an almost doubling of immune cell activity in healthy volunteers which were ingesting QuadraMune™ daily for a week.
Investigators analyzed blood for production of an immunological protein called "interleukin-2" after stimulation with anti-CD3 and anti-CD28. The substantial increase in interleukin-2 is believed to predict that immunological cells such as T cells and NK cells, which are needed to fight viruses such as SARS-CoV-2, possess enhanced function after QuadraMune™ administration.
Currently the Company is running a clinical trial on QuadraMune™ for preventing COVD-19 in health care workers. The clinical trial is listed on the National Institutes of Health Clinical Trial Database at www.clinicaltrials.gov.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Corporate Governance and Structure
As mentioned above, the Company is in the process of engaging a PCAOB certified accounting firm in order for the Company to become a fully reporting SEC filer. This will enable us to list in any public market as share value dictates and create a new level of shareholder confidence in the tradability of the stock. Additional capital structure is also envisioned, including adjustment of the authorized shares and clean-up of aged receivable and payables.
Go Forward Strategy
The company will continue to seek additional distribution partners for our CBD and Nutraceutical product lines while driving our online sales through strategic SEO campaigns. This strategy is designed to increase and add revenue through iBrands Farms agribusiness. The company plans to engage an audit firm to help us become fully reporting, and filing current financial statements with the appropriate regulatory authorities. The Company will reorganize and seek key financing partners in order to achieve our vision for the year and beyond.
We want to wish for the safety and health of our shareholders and their families at this time and thank you for your continued faith in iBrands Corporation’s future.
Warm Regards,
Patrick Johnson
CEO
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene visit www.nanostilbene.com.
About iBrands Farms
iBrands Farms is a vertically integrated agribusiness focused on the production and sale of hemp derived products with naturally occurring cannabinoids. Our mission is to efficiently deliver the highest quality industrial hemp-derived cannabinoid products and unique nutraceuticals to our customers, both retail and wholesale. The company can be found at www.ibrandsfarms.com
About iBrands Corporation
iBrands Corporation, Inc. is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade. The company can be found at: www.ibrandscorporation.com
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
For more information please contact:
patrick@ibrandscorporation.com
Sources:
https://www.yahoo.com/lifestyle/ibrands-corporation-adds-immune-booster-131010087.html
FAQ
What is the latest update from iBrands Corporation (IBRC)?
What products are included in the Master Sales Agreement with Therapeutic Solutions Inc. for IBRC?
How does QuadraMune affect immune cell activity according to the latest clinical trial results reported by IBRC?
Where can I find information about the clinical trial for QuadraMune by iBrands Corporation?
